Apr 20, 2017 - classic AIH.30 41 47â49 Centrilobular necrosis (CN) has been repeatedly ..... hepatitis (piecemeal necrosis), concluding that AIH with an acute.
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
JCP Online First, published on April 20, 2017 as 10.1136/jclinpath-2016-204271 Original article
Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients Hiep Nguyen Canh,1 Kenichi Harada,1 Hirofumi Ouchi,1 Yasunori Sato,1 Koichi Tsuneyama,2 Masayoshi Kage,3 Masayuki Nakano,4 Kaname Yoshizawa,5 Atsushi Takahashi,6 Masanori Abe,7 Jong-Hon Kang,8 Kazuhiko Koike,9 Ayano Inui,10 Tomoo Fujisawa,10 Akinobu Takaki,11 Teruko Arinaga-Hino,12 Takuji Torimura,12 Yoshiyuki Suzuki,13 Keiichi Fujiwara,14 Mikio Zeniya,15 Hiromasa Ohira,6 Atsushi Tanaka,16 Hajime Takikawa,16 Intractable Liver and Biliary Diseases Study Group of Japan For numbered affiliations see end of article. Correspondence to Dr Kenichi Harada, Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa 920-8640, Japan; kenichih@ med.kanazawa-u.ac.jp Received 2 December 2016 Revised 29 March 2017 Accepted 30 March 2017
ABSTRACT Aims Although liver biopsy is crucial to diagnose and guide treatment decisions, a detailed histological analysis of autoimmune hepatitis (AIH) with clinically acute presentations has not yet been performed. This study aimed to characterise the histological features and explore potential histological hallmarks to diagnose the acute presentation of AIH. Methods We systematically evaluated liver specimens of 87 adult patients with acute presentation of AIH retrospectively enrolled from Japanese multicentre facilities. Each histological feature was predefined by consensus based on the diagnostic criteria. Results Key findings were that acute presentation of AIH revealed histological features of both acute hepatitis and chronic hepatitis accompanying various degrees of fibrosis. The prominent features were lobular necrosis/ inflammation (97.7%), plasma cell infiltration (96.4%), emperipolesis (89.3%), pigmented macrophages (84.5%), cobblestone appearance of hepatocytes (82.6%) and perivenular necroinflammatory activity, including centrilobular necrosis (81.4%). Conclusions The acute presentation of AIH represents the entire histological spectrum of acute hepatitis and chronic hepatitis with various activity grades and fibrosis stages that clinically correspond to acute-onset AIH and acute exacerbation of classic AIH, respectively. Although there are no pathognomonic features for the pathological diagnosis, the prominent presence of lobular and perivenular necroinflammatory activity, pigmented macrophages and cobblestone appearance of hepatocytes in addition to the classic AIH features, such as plasma cell infiltration and emperipolesis, are useful for the pathological diagnosis of the acute presentation of AIH. INTRODUCTION
To cite: Nguyen Canh H, Harada K, Ouchi H, et al. J Clin Pathol Published Online First: [ please include Day Month Year] doi:10.1136/ jclinpath-2016-204271
Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory liver disorder characterised by autoantibodies, hypergammaglobulinemia, and interface hepatitis with lymphoplasmacytic infiltration on histological examination.1–3 Although defined as a chronic disease,4 AIH can have an acute presentation at its onset that mimics acute hepatitis of other causes (8.7–75%).5–20 In Japanese
nationwide surveys conducted in 2009 and 2015, 10.9% and 11.7%, respectively, of patients with AIH had a histological diagnosis of acute hepatitis.21 22 AIH may also present as acute severe hepatitis or even acute liver failure.16 23–30 Acute presentation of AIH may encompass two different clinical entities:30–34 (1) the acute exacerbation of underlying chronic AIH (acute exacerbation phase of classic AIH) with histological evidence of chronic hepatitis; and (2) the genuine, newly developed, acute-onset AIH (acute hepatitis phase of AIH) without histopathological findings of chronic liver diseases.6 7 20 24 28 29 34–39 Early diagnosis of AIH with an acute presentation remains challenging but urgent. There is no single diagnostic test for AIH. The diagnostic criteria for classic AIH proposed by the International Autoimmune Hepatitis Group have been standardised by consensus and include clinical, serological, biochemical and histological findings, as well as the absence of data suggestive of other diseases.40 41 However, some patients with acute presentation of AIH, atypical features such as normal serum immunoglobulin G (IgG) levels and/or negativity of autoantibody usually do not meet the diagnostic criteria.12 14 24 36 37 40–43 AIH showing an acute presentation may progress to severe hepatitis or acute liver failure with resistance to immunosuppressive therapy and catastrophic outcomes; thus, timely diagnosis is the most important factor for improving the poor prognosis of these patients.7 18 28 44–46 Liver biopsy evaluation is mandatory for precise, early diagnosis, but the histology of AIH with acute presentations is heterogeneous and may not reveal typical histological findings of classic AIH.30 41 47–49 Centrilobular necrosis (CN) has been repeatedly reported in AIH patients with acute presentations.6 16 34–36 50–58 In particular, CN with plasma cell infiltration is considered to be characteristic for AIH with acute presentations, but its significance remains to be elucidated; the centrilobular lesion with none to mild portal inflammation, without interface hepatitis and fibrosis, may represent characteristics of early AIH.50 55–57 However, histological features of AIH with an acute presentation showed wide-ranging
Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd under licence.
1
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article divergences among previous studies that were based on case reports, small cohorts of patients or those that mainly focused on clinical characteristics. Some found no significant difference in clinical laboratory features between AIH with an acute presentation and that with a chronic presentation.5 42 Further, a detailed histological analysis of acute presentation of AIH has not been performed. We hypothesised that the acute presentation of AIH should show a wide spectrum of histological features, which should change time dependently, including that of acute hepatitis, convalescent stages from acute hepatitis and acute exacerbation of chronic AIH. Herein, we performed a detailed histological evaluation on liver biopsies from a large cohort of patients with acute presentation of AIH. Our specific aims were to characterise the histological features and explore potential histological hallmarks to diagnose the acute presentation of AIH.
METHODS Patients The Autoimmune Hepatitis Group, a subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan, conducted a multicentre retrospective survey of patients with AIH who were admitted to eight tertiary hospitals with liver specialists, from 2005 to 2014. Overall, 87 adult patients with acute presentations of AIH, selected from the survey, were eligible for this study. The acute presentation of AIH was diagnosed based on the revised original criteria of the International AIH Group (1999) defining the score for definite or probable AIH40 and/or on an empirical judgment by experienced hepatologists on the basis of combining clinical, laboratory, serological and histological data. All patients showed response to immunosuppressive therapy, with a mean follow-up duration of 41±28.6 (1–115) months. Other aetiologies of liver diseases were strictly ruled out. The acute presentation of AIH was tentatively defined as AIH with (1) acute onset symptoms in conjunction with serum bilirubin levels of more than 5 mg/dL and/or serum alanine aminotransferase (ALT) levels of more than 10-fold the normal limit; and (2) no history of any prior liver disease.7 Patients with an overlap syndrome (overlap of AIH with other diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, autoimmune cholangitis) or a coexistent liver disease were excluded from this analysis.
Clinical and laboratory data The demographic and biochemical data collected from patients at the time of diagnosis were as follows: age, sex, time from onset to liver biopsy, bilirubin, aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), IgG, anti-nuclear antibody (ANA), anti-smooth muscle antibody (ASMA) and antimitochondrial antibody (AMA). This study was approved by the Fukushima Medical University Ethics Committee (no. 2099).
Histological evaluation Liver biopsy was performed before treatment, within 6 months from the onset of symptoms. Tissues from explants or autopsies were excluded. Biopsy specimens were stained with at least H&E and connective tissue stainings such as Masson’s trichrome and reticulin stainings. Five experienced pathologists reviewed all biopsy slides, using the same histological scoring sheet as in table 1, in which each histological feature was predefined by consensus based on the diagnostic criteria. Histological features evaluated on each biopsy were divided into two board categories: (1) lobular ( parenchymal) changes including CN 2
(collapse, lytic type), centrilobular congestion/haemorrhage, centrilobular endothelial cell injury/central vein endotheliitis, cobblestone appearance of hepatocytes, hepatic rosette formation in areas of cobblestone appearance, lobular pigmented macrophages (in CN, intralobular areas) and centriloblar fibrosis; (2) portal/periportal changes, including portal inflammation, interface hepatitis, portal plasma cell infiltration, hepatic rosette formation in periportal areas, bile duct injury and fibrosis. The features were noted as absent (−), present (+) or scored on a semiquantitative scale based on the severity of the lesion (0=none, 1=mild, 2=moderate and 3=severe) or other characterised as specified. The portal-based fibrosis was scored using the Batts-Ludwig scheme (0, no fibrosis; 1, portal fibrosis; 2, periportal fibrosis; 3, septal fibrosis; and 4, cirrhosis).59 Centrilobular fibrosis was recorded as none (no fibrosis), mild (fibrosis limited to perivenular areas, requiring collagen/fibre stain to detect), moderate (fibrosis limited to perivenular areas, visible on H&E staining), or severe (scar-like, board fibrosis). Plasma cell infiltration in lobular or portal/periportal areas was recorded as absent, mild (only occasional cells were identified), moderate (easily recognised plasma cells that were a minority of the inflammatory cell infiltrates) or severe (numerous plasma
Table 1
Histological features evaluated in this study
Features Lobular changes Centrilobular necrosis (CN) CN type: collapse CN type: lytic Centrilobular congestion/haemorrhage Centrilobular endothelial cell injury/central vein endotheliitis Perivenular necroinflammatory activity Lobular necrosis/inflammation (not including CN, for example: spotty, bridging or massive necrosis) Cobblestone appearance of hepatocytes
Value
Code
−, + −, + −, + −, + −, +
Absent, Absent, Absent, Absent, Absent,
−, + 0–3
Absent, present None, mild, moderate, severe
0−3
None, mild, moderate, severe Absent, present
−, +
Hepatic rosette formation in cobblestone appearance areas Lobular pigmented macrophages Pigmented macrophages in CN areas Lobular plasma cell infiltration
−, + −, + 0–3
Emperipolesis Centrilobular fibrosis
−, + 0–3
Portal/periportal changes Portal inflammation
0–3
Interface hepatitis
0–3
Portal plasma cell infiltration
0–3
Bile duct injury
0–2
Portal pigmented macrophages Hepatic rosette formation in periportal areas Fibrosis* Others Cholestasis
−, + −, + 0–4 0–3
present present present present present
Absent, present Absent, present None, mild, moderate, severe Absent, present None, mild, moderate, severe None, mild, moderate, severe None, mild, moderate, severe None, mild, moderate, severe None, mild or moderate, severe Absent, present Absent, present No fibrosis–cirrhosis None, mild, moderate, severe
*Fibrosis was assessed with the Batts–Ludwig scoring system.59
Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article cells present in groups and sheets in the portal tracts or as groups in the sinusoids).60 Cobblestone appearance of hepatocytes was defined as clusters of small, monomorphic hepatocytes with typically clear hydropic cytoplasm that tend to efface the liver cord arrangement, usually locate around the portal tracts or adjacent to fibrous septa, reflecting increased regenerative activity (figure 1).61 The presence and the extent of cobblestone appearance were assessed as none, mild (≤10% of the parenchyma affected), moderate (10–30% of the parenchyma affected), severe (>30% of parenchyma affected). Bile duct injury was assessed as none (score 0), mild or moderate injury (score 1) and severe injury (score 2) as previously described.62 Cholestasis was evaluated as none (no visible bile), mild (bile identified only after careful search under high magnification), moderate (bile not immediately evident at low magnification but easily found at high magnification, severe (bile easily found at low magnification).63 A modified Ishak scoring system was used to evaluate interface hepatitis, lobular necrosis/inflammation and portal inflammation.64 Interface hepatitis was recorded as absent, mild (focal, involving some or most of portal tracts), moderate (circumferential, involving minority, 10 foci and/or confluent necrosis). Portal inflammation was recorded as absent, mild (few inflammatory cells, involving some or most portal tracts), severe (marked inflammatory cells, involving some or most portal tracts) and moderate (moderate inflammatory cells, between the two entities).
Findings other than features listed in table 1 were also recorded. After the histological evaluation, cases with disagreement among the five pathologists were discussed. The final histological diagnosis was established based on consensual decision making by all pathologists. CN was defined as confluent hepatocellular necrosis in the centrilobular area or predominantly affecting the centrilobular area (figure 1). Emperipolesis was defined as engulfment of lymphocytes by hepatocytes; the engulfed lymphocytes morphologically remain intact and are surrounded by hepatocyte cytoplasm with a halo (figure 1). Engulfment of plasma cells by hepatocytes was excluded from this analysis.41 47 Perivenular necroinflammatory activity was defined as centrilobular injury, other than CN, with prominent hepatocellular necrosis and mononuclear inflammation, including spotty/focal necrosis (figure 1).52 65
Statistical analysis Data are reported as mean±SD or median (range) for continuous variables and proportion/frequency for dichotomous variables. Statistical analysis was conducted with SPSS Statistic for Mac OS V.18.0 (SPSS, Chicago, Illinois, USA). If there were missing values, the analysis was performed with available data.
RESULTS Patient characteristics Clinical and laboratory features of AIH with acute presentations are summarised in table 2. Eighty-seven patients with AIH who had acute presentations of the disease were enrolled. Patients were predominantly female (female:male ratio, 6:1), with a mean age of 54.5±15.3 (range, 16–84) years.
Figure 1 Examples of some histological features of autoimmune hepatitis with an acute presentation. (A) Centrilobular necrosis (CN) without the involvement of portal tracts (P). (B) Higher magnification of the panel (A) reveals a typical CN with confluent hepatocellular necrosis/dropout and mononuclear inflammation including some plasma cells (arrowheads) around a central vein (CV). (C) The right half of the hepatic parenchyma, from the fibrous septa with a hepatic rosette (arrow), represents the cobblestone appearance with small and hydropic hepatocytes. (D) Hepatic rosette formation (arrow). There is also the presence of CN with centrilobular haemorrhage. (E) Perivenular necroinflammatory activity. (F) Emperipolesis (arrow) (H&E (A–F), original magnifications: (A) ×50, (B–E) ×200, (F) ×400).
Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
3
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article Table 2 Clinical and serological features of patients with acute presentation of AIH at initial liver function tests Values (n=87) Age (years), mean±SD (range) Sex (female/male) Days from onset to biopsy, median (range) AST (IU/L)* ALT (IU/L)* ALP (IU/L)* Total bilirubin (mg/dL), mean (range) IgG (mg/dL)* ANA (titre), ≥1:40 ASMA (titre), ≥1:40 ANA±ASMA (titre), ≥1:40 AMA (titre), ≥1:40 AMA-M2, positive
54.5±15.3 (16–84) 75/12 21 (1–180) 700±545.4 839.7±606.5 546.5±276.6 6.2 (0.4–31.3) 1984.7±820 64/86 (74.4%) 12/49 (24.5%) 67/86 (77.9%) 3/54 (5.5%) 12/73 (16.4%)
*Values are mean±SD. AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; AMA-M2, antimitochondrial M2 antibodies; ANA, antinuclear antibodies; ASMA, anti-smooth muscle antibodies, AST, aspartate aminotransferase; IgG, immunoglobulin G.
The median days from the onset of symptoms to biopsy was 21 (range 1–180) days, and 85.1% of the biopsy specimens were taken within 3 months from the onset of symptoms. The mean (±SD) serum IgG level at onset was 1984.7±820 mg/dL. Almost 78% of patients tested positive for ANA and/or ASMA, 74.4% for ANA and 5.5% for AMA.
Histological findings
Histological features of AIH with acute presentations revealed various patterns of hepatic injury and are summarised in table 3. The spectrum of histological features ranged from early stages, mild acute lobular hepatitis with virtually unaffected portal and periportal areas (figure 2), through chronic hepatitis with severe activity and negligible fibrosis (figure 3) to severe necroinflammatory lesions in chronic hepatitis with advanced stages of fibrosis (stage 3) (figure 4). However, lobular necrosis/inflammation, plasma cell infiltration in lobular and/or portal areas, emperipolesis, pigmented macrophages, cobblestone appearance of hepatocytes, perivenular necroinflammatory activity and/or CN were the most striking features of AIH with acute presentations. The presence (+) or score ≥1 of each finding was evaluated as a positive one in calculating each value. The frequency of plasma cell infiltration in lobular and/or portal areas was high at 96.4%. Approximately 90% of patients showed emperipolesis, 84.5% pigmented macrophages (regardless of the areas), and 81.4% perivenular necroinflammatory and/or CN. CN was usually observed, but there was no significant difference in the frequency between collapse (39.5%) and lytic (44.0%) types. Perivenular necroinflammatory activity was more frequent than CN. Portal inflammation was frequently accompanied by plasma cell infiltration (91.6% of all cases). The proportion of interface hepatitis was 75%, and hepatic rosette formation (in cobblestone and/or periportal areas) was 60.5%. Other common findings were centrilobular endothelial cell injury/central vein endotheliitis, fibrosis (stage 1–3, 67.4%), centrilobular fibrosis and centrilobular congestion/haemorrhage. Bile duct injury was commonly seen, but only 7/84 (8.3%) cases showed severe damage. Cholestasis was present in 12 (14%) cases (8 cases of mild cholestasis, 4 cases of moderate cholestasis). No case of cirrhosis was observed. 4
DISCUSSION
To date, no standardised definition or acceptable diagnostic criteria have been established for the acute presentation of AIH, although this entity has long been recognised.10 66 Liver biopsy is crucial to diagnose AIH and guide treatment decisions. However, the morphological spectrum of AIH with an acute presentation has not yet been clarified and remains controversial. This study aimed to address the issue by systematically evaluating liver biopsies from a large cohort of patients with acute presentations of AIH. To our knowledge, this is the largest performed series to date. Key findings were that AIH with acute presentations represented a broad histological spectrum of both acute hepatitis and chronic hepatitis, ranging from mild acute lobular hepatitis to severe inflammatory lesions in chronic hepatitis with advanced stage of fibrosis, but without cirrhosis. The most striking features were lobular necrosis/inflammation, plasma cell infiltration in lobular and/or portal areas, emperipolesis, pigmented macrophage, cobblestone appearance of hepatocytes and perivenular necroinflammatory activity, including CN. The present data revealed various histological patterns of AIH with acute presentations reported in earlier studies, in which histological features of acute hepatitis, including CN, submassive necrosis and massive necrosis, were present in 12.2–88% cases.6 7 20 24 28 29 34–39 However, as mentioned, individual histological features were less specified and their proportions were widely different among previous reports.5–7 16 24 27–29 35 36 38 42 Particular attention was paid to CN. In earlier reports,16 22 34–36 52 67 CN frequency varied from 21.8% to 100% of AIH patients with acute presentations compared with 57% in the present study. The reason for this divergence is unclear, but several feasible explanations can be proposed, such as patient populations with different diagnostic criteria, differences in disease severities, differences in the histological definition of CN among reports and/or natural heterogeneity of the disease. CN has been more frequently found in the acute hepatitis phase (100%) than in the acute exacerbation phase of AIH (42%).34 Its prevalence also increases with disease severity.37 Thus, patient populations with a higher rate of severe hepatitis or fulminant hepatitis cases may have a higher frequency of CN.34 37 Another reason is inconsistency in the diagnostic criteria of CN.52 Some prior studies regarded both confluent necrosis (defined as CN in the present study) and spotty (focal) necrosis in centrilobular areas as CN.16 54 Our data actually showed that the rate of CN and/or perivenular necroinflammatory activity was also high (81.4%). The significance of CN in AIH remains to be clarified, but numerous data support the concept that CN is a histological characteristic of AIH with acute presentations. Indeed, our material revealed some cases with CN and virtually unaffected portal tracts (figure 1). Interestingly, some other cases showed lobular hepatitis with mild portal inflammation without CN or demonstrated lobular hepatitis without an involvement of centrilobular and/or portal areas (figure 2). These cases represented a wide histological spectrum of early-stage AIH with variously combining lesions in lobular, centrilobular and portal areas, including features of the convalescent stage of acute hepatitis. Furthermore, CN was more often observed in AIH with an acute presentation than in that with a chronic presentation (53% vs 17.5–30.7%).22 34 51 53 68 Hofer et al51 reported that patients with AIH and CN more frequently have an acute presentation of disease than those without CN. Some CN cases without or with minimal portal involvement, representing typical acute hepatitis, may progress to classic AIH, although other cases may not.35 50 54–57 Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article Table 3 Histological features of autoimmune hepatitis with an acute presentation Features
Values (n=87)
Lobular (parenchymal) changes Lobular necrosis/inflammation, score ≥1 (not including CN, for example: spotty, bridging, or massive necrosis) Emperipolesis (+) Lobular plasma cell infiltration, score ≥1 Cobblestone appearance of hepatocytes, score ≥1 Perivenular necroinflammatory activity (+) Lobular pigmented macrophages (+) Pigmented macrophages in CN areas (+) Centrilobular endothelial cell injury/central vein endotheliitis (+) Centrilobular fibrosis, score ≥1 Centrilobular congestion/haemorrhage (+) Centrilobular necrosis (CN) (+) CN type: collapse (+) CN type: lytic (+) Hepatic rosette formation in cobblestone appearance areas (+) Portal/periportal changes Portal inflammation, score ≥1 Portal plasma cell infiltration, score ≥1 Interface hepatitis, score ≥1 Fibrosis, stage 0/1/2/3/4 Portal pigmented macrophages (+) Bile duct injury, score ≥1 Hepatic rosette formation in periportal areas (+) Others Cholestasis, score ≥1
Emperipolesis has been widely described in classic AIH and included in the simplified International Autoimmune Hepatitis Group scoring system (2008).41 69 The presence of emperipolesis indicates a close immune interaction between lymphocytes and hepatocytes, which may subsequently induce hepatocyte apoptosis and has been proposed as an additional mechanism of autoimmune-mediated liver injury in AIH. The frequency of emperipolesis found in the present study was far higher than that of the 2015 Japanese nationwide survey,22 which was also higher than the rate reported in classic AIH.68–70 Interestingly, emperipolesis was found to be more frequent in AIH patients with acute hepatitis than in those with chronic hepatitis (21.7% vs 12.2%, p=0.02).22 This may be a justification for our higher frequency than that of classic AIH, and emperipolesis may have been underestimated in the 2015 Japanese nationwide survey. Plasma cell infiltration is a hallmark of AIH, although it is not a specific feature. We frequently found plasma cells, in lobular and/or portal areas, at a rate of 96.4% (lobular 85.7%, portal 91.6%), which was similar to that reported by Fujiwara et al36 67 (93–100%), Burgart et al42 (100%), and Takahashi et al (87.6%).22 Besides portal areas, we frequently found plasma cells in hepatic lobules (85.7%), including CN areas that were more likely to be involved in early stages of the disease. Interestingly, the infiltration of plasma cells in central areas reportedly occurred during the acute phase of AIH, but not during acute hepatitis caused by hepatitis virus and drug-induced liver injury (DILI).24 Thus, our data confirm that CN with plasma cell infiltration is useful for supporting the diagnosis of AIH with acute presentations. Compared with other histological features reported previously, the present data show both similarities and broad differences as follows (our data vs other studies): hepatic rosette formation Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
84/86 75/84 72/84 71/86 66/84 65/84 40/84 58/84 52/84 50/84 49/86 34/86 37/84 44/84
(97.7%) (89.3%) (85.7%) (82.6%) (78.6%) (77.4%) (47.6%) (69.0%) (61.9%) (59.5%) (57.0%) (39.5%) (44.0%) (52.4%)
78/84 76/83 63/84 28 47/84 42/84 34/83
(92.9%) (91.6%) (75.0%) (32.5%)/36 (41.9%)/20 (23.3%)/2(2.3%)/0 (56.0%) (50.0%) (41.0%)
12/86 (14%)
(60.5% vs 14.6–55.6%),22 24 27 34 35 58 interface hepatitis (75% vs 66.7–92.3%),5 22 35 36 42 58 bile duct injury (50% vs 21.1– 77.8%),22 58 fibrosis (67.4% vs 40–96.1%),5 6 16 22 34 36 42 67 end-stage fibrosis (stage 4) (0% vs 0–33.3%),5–7 14 16 42 portal inflammation (92.9% vs 90–100%),16 22 35 lobular necrosis/ inflammation (97.7% vs 73–100%)5 16 22 27 42 67 and cobblestone appearance of hepatocytes (82.6% vs 44.4%, 8/18 cases).27 It is worth noting that the frequencies of fibrosis and interface hepatitis varied markedly among studies, which may have led to controversial conclusions in the clinicopathological characteristics of AIH with acute presentations compared with classic AIH. Indeed, the rates of fibrosis and interface hepatitis reported previously5 42 were higher than those in the present study. In 1994, Nikias et al5 reported 12 cases of acute presentation of AIH. Of those, 75% showed fibrosis, 27% cirrhosis and 91.7% interface hepatitis (piecemeal necrosis), concluding that AIH with an acute presentation is indistinguishable by clinical laboratory features from the chronic presentation. Likewise, in 1995, Burgart et al42 evaluated 26 patients with acute presentation of AIH, of which 25/26 (96.1%) presented portal inflammation and fibrosis, with overt cirrhosis in 4 cases (15%) and interface hepatitis in 24/26 (92.3%). In contrast, Fujiwara et al and Takahashi et al reported lower proportions of fibrosis at 44.4% and 53.9%, respectively.22 67 Furthermore, fibrosis, particularly advanced-stage fibrosis (stage 3, 4), has been less frequently observed in AIH with acute presentations compared with that in AIH with chronic presentations.16 22 34 Causes of this divergence are unclear, but possible explanations are varied in diagnostic criteria as indicated above. Portal inflammation and lobular necrosis/inflammation showed similarities between our study and other reports with high frequencies. Although patients with histological features of acute liver failure (submassive or massive necrosis) were not 5
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article Figure 2 A histological spectrum of early-stage autoimmune hepatitis with an acute presentation. (A–B) Case no. 47. A biopsy performed 10 days after presentation reveals lobular changes with negligible perivenular injury (A) and mild portal inflammation (A–B); high-power view of portal inflammation (B) showing mixed inflammatory infiltrates with prominent lymphocytes, plasma cells (arrowheads) and pigmented macrophages. (C, D) Case no. 38. Prominent perivenular necroinflammatory activity with virtually uninvolved portal tracts (P). Areas around the central veins (CV) reveal focal (spotty) necrosis marked by the presence of pigmented macrophages and lymphocytes (D); the nearby portal tract is intact (D). (E, F) A representative case showing histological features of a convalescent stage from acute hepatitis with virtually sparing portal and centrilobular areas. The hepatic parenchyma shows minimal injuries (F) consisting of emperipolesis (arrow) and focal necrosis highlighted by pigmented macrophages (arrowhead) (case no. 35, the biopsy performed 142 days after the onset of symptoms). (H&E (A–F), original magnifications: (A, C, E) ×50, (B, D) ×200, (F) ×400).
Figure 3 Histopathology of autoimmune hepatitis with acute presentations. Low magnification shows severe portal inflammation and marked lobular necroinflammatory changes (A). (B) No apparent portal fibrosis is present (F0). (C) Severe portal inflammatory infiltrates with interface hepatitis contains many plasma cells (arrowheads). (D) The lobular area shows small clusters of mononuclear inflammatory cells, including some plasma cells (arrowheads), indicating sites of hepatocyte necrosis (H&E (A, C, D), Masson’s trichrome stain (B), original magnifications: (A) ×50, (B) ×100, (C–D) ×400.)
included in the present study, cases with these histological patterns have repeatedly been reported.24 25 27–29 42 Portal inflammation was almost always found, accounting for 92.9% of our patients (90–100% in other studies),16 22 35 including in early-biopsy cases with a mild lobular injury and without any evidence of disease chronicity. Accordingly, AIH with acute presentations can present in a wide histological spectrum of 6
acute hepatitis. Further, portal inflammatory infiltration, like in acute viral hepatitis, may occur in the acute hepatitis phase of AIH and may not be specific for chronic AIH. More importantly, findings that comprise focal (spotty) necrosis in hepatic lobules without any other changes, but with mild portal inflammation, though unspecific, should not preclude a diagnosis of AIH. The appearance of plasma cells in the hepatic lobules and/ Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article Figure 4 Histopathology of autoimmune hepatitis with acute presentations. (A) A portal tract is expanded with mononuclear inflammatory cell infiltrates and bridging fibrosis highlighted by Masson’s trichrome stain (C). (B) Marked portal enlargement and massive hepatocellular necrosis with severe inflammatory infiltration and bile duct proliferation. (D) Higher magnification shows hydropic degeneration of hepatocytes and lobular plasma cell infiltration (arrowheads). (H&E (A, B, D), original magnifications: (A–C) ×50, (D) ×400.)
or portal tracts may be suggestive of AIH in this setting. Besides, in the liver specimens, we often found pigmented macrophages (84.5%) and cobblestone appearance of hepatocytes (82.6%), which indirectly indicate disease activity. The evaluation of these lesions may be helpful for the diagnosis and prognosis of AIH with acute presentations, particularly in the covalence stage when necroinflammatory activity has reduced.71 Histologically, differentiating AIH from viral hepatitis and DILI, particularly DILI with AIH features (drug-induced AIH), can be challenging or indistinguishable.72 73 The prominent histological features indicated above are also present in many other acute or chronic liver diseases.60 63 74 75 However, when occurring in combination, they may favour a diagnosis of AIH. Portal and lobular plasma cells, hepatic rosette formation and emperipolesis have been reported to be features that favour AIH over DILI and viral hepatitis.24 60 70 Our study had a number of strengths and limitations. This multicentre study provided us with the unique opportunity to perform a systematic histological assessment in a large cohort of patients. The histological review was conducted by experienced hepatic pathologists. Additionally, the key histological features were predefined by consensus. The fact that no gold standard exists for the diagnosis of AIH with acute presentations is a limitation of our analyses. However, patients were retrospectively enrolled, and they showed response to immunosuppressive therapy on follow-up; this warranted our diagnosis and results of histological evaluation. Without a control group, we could not indicate whether there are particular histological features that should suggest AIH with acute presentations, as opposed to other diseases, but this was not the aim of the present study. Herein, we found that AIH with acute presentation is associated with a variety of histological changes, occurring at all stages of the disease, but cirrhosis. The most prominent features were lobular necrosis/inflammation, plasma cell infiltration in lobular and/or portal areas, emperipolesis, pigmented macrophages, cobblestone appearance of hepatocytes, perivenular necroinflammatory activity and/or CN and interface hepatitis. Portal inflammation can occur in early AIH. There are no histological features that are pathognomonic, but lobular necrosis/ inflammation, particularly CN, plasma cell infiltration, emperipolesis and pigmented macrophages are characteristics of the acute Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
presentation of AIH. In conclusion, the acute presentation of AIH represents the entire histological spectrum of acute hepatitis and chronic hepatitis with various activity grades and all fibrosis stages. We do encounter AIH that both clinically and histopathologically qualifies as acute hepatitis in our daily practice. We should recognise this wide histological spectrum of AIH to make a timely diagnosis and appropriate treatment decisions.
Take home messages ▸ Approximately 9–75% of autoimmune hepatitis (AIH) cases can have an acute clinical presentation that mimics acute hepatitis of other causes. ▸ The acute presentation of AIH can represent the entire histological spectrum of acute hepatitis and chronic hepatitis with various activity grades and fibrosis stages. ▸ The prominent presence of lobular and perivenular necroinflammatory activity, including centrilobular necrosis, pigmented macrophages and cobblestone appearance of hepatocytes, together with the classic AIH features ( plasma cell infiltration and emperipolesis) are useful to support the pathological diagnosis of AIH with acute presentation.
Author affiliations 1 Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan 2 Department of Pathology Lab. Med., Tokushima University, Graduate School, Tokushima, Japan 3 Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan 4 Division of Diagnostic Pathology, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan 5 Department of Gastroenterology, National Hospital Organization, Shinshu Ueda Medical Center, Ueda, Japan 6 Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan 7 Department of Gastroenterology and Metabiology, Ehime University Graduate School of Medicine, Ehime, Japan 8 Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan 9 Department of Gastroenterology and Hepatology, The Third Hospital of Jikei University School of Medicine, Tokyo, Japan 7
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article 10 Department of Pediatric Hepatology and Gastroenterology, Eastern Yokohama Hospital, Yokohama, Japan 11 Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 12 Department of Medicine, Kurume University School of Medicine, Kurume, Japan 13 Department of Hepatology, Toranomon Hospital, Tokyo, Japan 14 Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan 15 Sanno Medical Center, International University of Health and Welfare, Tokyo, Japan 16 Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
Handling editor Cheok Soon Lee Twitter Follow Hiep Nguyen Canh @Nguyen Canh Hiep Contributors Each of the authors contributed to the manuscript. The concept of this study was created by the Intractable Liver and Biliary Diseases Study Group of Japan. KH, KT, MK and MN developed the protocol. KH, KT, MK, MN, HO, YS and HNC reviewed the slides, collected, analysed and interpreted the data. HNC drafted the manuscript and KH critically revised the manuscript. KY, AT, MA, J-HK, KK, AI, TF, AT, TA-H, TT, YS, KF, MZ, HO, AT and HT identified clinical cases, and collected data. All authors read and approved the final manuscript. Funding This study was conducted and supported by the Health Labour Science Research Grants from Research on Measures for Intractable Diseases, the Intractable Hepato-Biliary Diseases Study Group in Japan and grant No. 26460416 from the Japan Society for the Promotion of Science (KH). HNC received the Japanese Government (Monbukagakusho: MEXT) Scholarship, No. 153345. Competing interests None declared. Patient consent Obtained. Ethics approval Fukushima Medical University Ethics Committee (no.2099). Provenance and peer review Not commissioned; externally peer reviewed.
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
REFERENCES 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
8
Liberal R, Grant CR, Mieli-Vergani G, et al. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013;41:126–39. Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver 2016;10:177–203. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011;8:320–9. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54–66. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866–71. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263–70. Yamamoto K, Miyake Y, Ohira H, et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res 2013;43:630–8. Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051–7. Kim BH, Kim YJ, Jeong SH, et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. J Gastroenterol Hepatol 2013;28:128–34. Lefkowitch JH, Apfelbaum TF, Weinberg L, et al. Acute liver biopsy lesions in early autoimmune (‘lupoid’) chronic active hepatitis. Liver 1984;4:379–86. Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res 2001;21:213–19. Miyake Y, Iwasaki Y, Kobashi H, et al. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig Liver Dis 2010;42:210–15. Miyake Y, Iwasaki Y, Kobashi H, et al. Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis. Hepatol Res 2009;39:241–6. Ferrari R, Pappas G, Agostinelli D, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the ‘acute’ type. QJM 2004;97:407–12. Michalska Z, Radowska D, Staike P, et al. Autoimmune hepatitis in the material of department and regional hospital of infectious diseases in Gdansk. Med Sci Monit 2003;9 (Suppl 3):P49–54. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625–31. Morii K, Nagano Y, Yamamoto T, et al. Increasing incidence of elderly-onset autoimmune hepatitis. Geriatr Gerontol Int 2016. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541–7.
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713–17. Yoshizawa K, Joshita S, Matsumoto A, et al. Incidence and prevalence of autoimmune hepatitis in the Ueda area, Japan. Hepatol Res 2016;46:878–83. Abe M, Mashiba T, Zeniya M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011;46:1136–41. Takahashi A, Arinaga-Hino T, Ohira H, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol 2016:1–10. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990;116:280–2. Abe M, Onji M, Kawai–Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007;5:255–8. Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011;53:517–26 Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23:1347–53. Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011;46:378–90. Fujiwara K, Yasui S, Yokosuka O. Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure. Hepatol Int 2013;7:335–46. Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res 2011;41:133–41. Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013;58:897–914. Onji M. The Autoimmune Hepatitis Study Group. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 2011;41:497–7. Ohira H, Abe K, Takahashi A, et al. Autoimmune hepatitis: recent advances in the pathogenesis and new diagnostic guidelines in Japan. Intern Med 2015;54:1323–8. Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res 2011;41:498–504. Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 2010;42:51–4. Abe K, Kanno Y, Okai K, et al. Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis. World J Hepatol 2012;4:262–7. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 2008;43:951–8. Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int 2011;31:1013–20. Fujiwara K, Fukuda Y, Seza K, et al. High level of persistent liver injury is one of clinical characteristics in treatment-naïve acute onset autoimmune hepatitis: experience in a community hospital. J Hepatobiliary Pancreat Sci 2016;23:174–80. Fujiwara K, Yasui S, Yonemitsu Y, et al. Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. J Hepatobiliary Pancreat Sci 2016;23:212–19. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–76. Burgart LJ, Batts KP, Ludwig J, et al. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Sur Pathol 1995;19:699–708. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50:538–45. Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014;61:876–82. Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 2013;43:97–105. Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr 1990;11:138–40. Harada K. Histological findings of autoimmune hepatitis. In: Ohira H, ed. Autoimmune liver diseases: perspectives from Japan. Tokyo: Springer Japan, 2014:45–65. Abe M, Onji M. Acute presentation of autoimmune hepatitis In: Ohira H, ed. Autoimmune liver diseases: perspectives from Japan. Tokyo: Springer Japan, 2014:83–94. Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute-onset autoimmune hepatitis. Hepatology 2011;54:371–2. Singh R, Nair S, Farr G, et al. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97:2679–3.
Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Original article 51 52 53 54 55 56 57 58 59 60 61 62
63
Hofer H, Oesterreicher C, Wrba F, et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246–9. Aizawa Y, Abe H, Sugita T, et al. Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol 2016;28:391–7. Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007;37:801–5. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Sur Pathol 2004;28:471–8. Pratt DS, Fawaz KA, Rabson A, et al. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664–8. Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 1997;41:269–71. Zen Y, Notsumata K, Tanaka N, et al. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007;38:1669–75. Iwai M, Jo M, Ishii M, et al. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008;38:784–9. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Sur Pathol 1995;19:1409–17. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824–32. Nakanuma Y, Harada K, Noromura A, et al. Pathology of autoimmune hepatitis and related diseases. In: Nishioka M, Toda G, Zeniya M, eds. Autoimmune hepatitis. Amsterdam: Elsevier, 1994:85–127. Zen Y, Harada K, Sasaki M, et al. Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol 2005;40:164–70. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59:661–70
Nguyen Canh H, et al. J Clin Pathol 2017;0:1–9. doi:10.1136/jclinpath-2016-204271
64 65 66 67 68 69 70 71
72 73 74 75
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9. Washington MK, Manns MP. Autoimmune hepatitis. In: Portmann BC, Ferrell LD, eds. MacSween’s pathology of the liver (sixth edition). Edinburgh: Churchill Livingstone, 2012:467–90. Crapper RM, Bhathal PS, Mackay IR, et al. ‘Acute’ autoimmune hepatitis. Digestion 1986;34:216–25. Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology 2011;58:693–704. Miao Q, Bian Z, Tang R, et al. Emperipolesis mediated by CD8T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol 2015;48:226–35. Tiniakos DG, Brain JG, Bury YA. Role of histopathology in autoimmune hepatitis. Dig Dis 2015;33(Suppl 2):53–64. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011;54:931–9. Grønbæk H, Kreutzfeldt M, Kazankov K, et al. Single-centre experience of the macrophage activation marker soluble (s)CD163—associations with disease activity and treatment response in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2016;44:1062–70. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040–8. Hisamochi A, Kage M, Ide T, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol 2016;51:597–607. Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015;180:40–51. Mietkiewski JM, Scheuer PJ. Immunoglobulin-containing plasma cells in acute hepatitis. Liver 1985;5:84–8.
9
Downloaded from http://jcp.bmj.com/ on April 20, 2017 - Published by group.bmj.com
Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients Hiep Nguyen Canh, Kenichi Harada, Hirofumi Ouchi, Yasunori Sato, Koichi Tsuneyama, Masayoshi Kage, Masayuki Nakano, Kaname Yoshizawa, Atsushi Takahashi, Masanori Abe, Jong-Hon Kang, Kazuhiko Koike, Ayano Inui, Tomoo Fujisawa, Akinobu Takaki, Teruko Arinaga-Hino, Takuji Torimura, Yoshiyuki Suzuki, Keiichi Fujiwara, Mikio Zeniya, Hiromasa Ohira, Atsushi Tanaka and Hajime Takikawa J Clin Pathol published online April 20, 2017
Updated information and services can be found at: http://jcp.bmj.com/content/early/2017/04/20/jclinpath-2016-204271
These include:
Supplementary Supplementary material can be found at: Material http://jcp.bmj.com/content/suppl/2017/04/20/jclinpath-2016-204271.D C1
References Email alerting service
This article cites 69 articles, 4 of which you can access for free at: http://jcp.bmj.com/content/early/2017/04/20/jclinpath-2016-204271 #BIBL Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Notes
To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://group.bmj.com/subscribe/